248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
Abstract
Proteinuria in chronic kidney disease (CKD) is a strong risk predictor for adverse cardiorenal outcomes. However, non-proteinuric CKD in type 2 diabetes (T2D) is rarely studied in clinical trials despite epidemiological evidence indicating a recent shift towards this phenotype. We explored the effect of empagliflozin (EMPA) on cardiorenal outcomes in a subgroup of patients from EMPA-REG OUTCOME with non-proteinuric CKD at baseline. 7020 patients with T2D and prior CV disease were treated with EMPA 25mg, 10mg or placebo (PBO) (median follow-up of 3.1 years). Post hoc, Cox regression assessed effects of EMPA vs. PBO on the composite outcome of CV death/HHF, CV death, HHF, a composite kidney outcome of incident/worsening nephropathy and all-cause mortality. Non-proteinuric CKD was defined as low eGFR and absence of overt albuminuria (eGFR Disclosure S.E. Inzucchi: Consultant; Self; vTv Therapeutics, Zafgen, Inc. Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi. B. Zinman: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. Consultant; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. J. George: Employee; Self; Boehringer Ingelheim International GmbH. M.…
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.